Is Twist Bioscience Corporation (TWST) a Strong Buy After Guggenheim Lifts Price Target?

We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. Twist Bioscience Corporation (NASDAQ:TWST) is among the best immunology stocks.

TheFly reported on May 5 that a Guggenheim analyst increased the price target on TWST from $55 to $60 while maintaining a Buy rating on the stock. The revision followed the company’s latest quarterly results and came ahead of its investor day held on May 21. The adjustment reflects updated financial estimates and expectations after recent performance data. The analyst’s note highlighted continued positive sentiment toward the company’s outlook, with valuation changes incorporated based on the most recent earnings report and upcoming strategic presentation to investors.

Twist Bioscience Corporation (NASDAQ:TWST) reported its fiscal second quarter 2026 financial results on May 4, 2026, covering the period ended March 31, 2026. The company recorded revenue of $110.7 million, representing 19% year-over-year growth, driven by gains in both DNA Synthesis and Protein Solutions as well as NGS Applications. Gross margin improved to 51.6%, while research and development expenses declined compared to the prior year period. Selling, general, and administrative expenses increased year over year, contributing to a wider net loss of $44.0 million, or $0.71 per share. Adjusted EBITDA showed a modest improvement but remained negative at $13.3 million.

Is Twist Bioscience Corporation (TWST) a Strong Buy After Guggenheim Lifts Price Target?

The company ended the quarter with approximately $172 million in cash and investments and raised its full-year outlook, projecting continued revenue growth and gross margin expansion, with expectations of approaching adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that engineers synthetic DNA on silicon to support immunology and drug discovery. It provides tools like antibody discovery platforms, DNA libraries, and sequencing solutions to help researchers study and engineer the immune system.

While we acknowledge the risk and potential of TWST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TWST and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1